RxDoctor Payments Data

Agustus Beck, MD

Internal Medicine · Chardon, OHNPI 1154314797

Payments from drug & device makers

$28,159in general payments, 2019–2025

Across 960 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$13K
  • AstraZeneca$1K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • Boston Scientific$968
  • Novartis$929
  • plus $10K from 36 others

What the payments were for

  • Speaking & faculty fees$11,20040%
  • Travel & lodging$590%
  • Food & beverage$16,76360%
  • Education$1370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,159 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$593,589
Medicare patients
1,107
Services billed
11,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban717$912,368
XareltoRivaroxaban257$327,799
JardianceEmpagliflozin141$151,491
Repatha SureclickEvolocumab94$72,840
EntrestoSacubitril/Valsartan49$58,976
FarxigaDapagliflozin Propanediol15$25,386
OzempicSemaglutide20$20,425
BrilintaTicagrelor14$17,220
Praluent PenAlirocumab24$16,044
VerquvoVericiguat12$15,975
Metoprolol Succinate941$15,310
Dofetilide37$8,948
Nebivolol Hcl76$6,077
ClopidogrelClopidogrel Bisulfate538$5,873
Ezetimibe172$5,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$925$912,368717 claims
Johnson & JohnsonXarelto$12,672$327,799257 claims
Boehringer IngelheimJardiance$1,247$151,491141 claims
NovartisEntresto$929$58,97649 claims
AstraZenecaFarxiga, Brilinta$1,493$42,60629 claims
Novo NordiskOzempic$497$20,42520 claims
MerckVerquvo$615$15,97512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Chardon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →